Apollomics Inc (APLM)
Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies designed to engage the immune system and target molecular pathways involved in cancer growth. The company’s pipeline includes Vebreltinib (APL-101), an oral and highly selective c-Met inhibitor being evaluated in Phase 2 trials for non-small cell lung cancer and other solid tumors with MET dysregulation. Other candidates include APL-102, a small-molecule multi-tyrosine kinase inhibitor in Phase 1 testing, and APL-122, which is being studied in Phase 1 dose-escalation trials for cancers within the brain. Apollomics also has immuno-oncology programs that include APL-501, APL-502, and APL-801. Founded in 2015, the company is based in Foster City, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-APLM
|
$20.89
|
12.8% Upside
|
Fair
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-3.7x
|
-12.8x
|
4.6x
|
41.418 M
|
38.038 M
|
1.5%
|
56.6%
|
-149.1
|
—
|
94.8%
|
